Core Viewpoint - Willis Lease Finance Corporation announced a quarterly dividend of $0.40 per share, reflecting the strength of its business and commitment to long-term shareholder value [1][2]. Company Overview - Willis Lease Finance Corporation (WLFC) is a leading lessor of commercial aircraft engines and provides global aviation services, including leasing large and regional spare commercial aircraft engines and aircraft to various stakeholders [3]. - The company's services are integrated with engine and aircraft trading, engine lease pools, asset management services, and end-of-life solutions for engines and aviation materials [3]. - WLFC also offers maintenance services through its subsidiaries, including Part 145 engine maintenance, aircraft line and base maintenance, and ground handling services [3].

VAL-D’OR, Quebec, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cartier Resources Inc. (″ Cartier ″ or the ″ Company ″) (TSXV: ECR; FSE: 6CA) is pleased to announce the sixth batch of results from Main Sector from the 100,000-m drilling program (2 drill rigs) on its 100%-owned Cadillac Project, located in Val-d’Or (Abitibi, Quebec). Strategic Highlights from Main Sector Drill Hole Results (Figures 1 to 4)5B3/5C3 Zones CA25-300 intersected 29.6 g/t Au over 1.7 m including 54.3 g/t Au over 0.9 m (5B3 Zone).CA25-303 grade ...

CINCINNATI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced its tax reporting information for the 2025 distributions to holders of its common stock. The tax reporting information as it will be reported on the Form 1099-DIV, on a per share basis, is as follows: Nasdaq-Listed Common Shares; CUSIP 71844V201 Record DatePayab ...

Core Insights - Dyne Therapeutics has received Orphan Drug designation in Japan for zeleciment basivarsen (z-basivarsen) to treat myotonic muscular dystrophy type 1 (DM1), highlighting the urgent need for new therapies in this area [1][2] - Z-basivarsen has shown early and sustained improvements in myotonia, muscle strength, and function, with a favorable safety profile, and has also received similar designations in the U.S. and Europe [2][4] - The ACHIEVE trial is a Phase 1/2 clinical trial evaluating z-basivarsen, with a registrational dose of 6.8 mg/kg administered every eight weeks, aiming for potential regulatory submissions [3][4] Company Overview - Dyne Therapeutics focuses on delivering functional improvement for individuals with genetically driven neuromuscular diseases, including DM1 and Duchenne muscular dystrophy (DMD) [6][7] - The company is advancing clinical programs targeting muscle and the central nervous system to address the root causes of these diseases [7] Clinical Trial Details - The ACHIEVE trial is a global, randomized, placebo-controlled, double-blind study assessing the safety, tolerability, and efficacy of z-basivarsen in DM1 patients [3] - The primary endpoint for the registrational expansion cohort is the change in middle finger myotonia measured by video hand opening time (vHOT) at 6 months compared to placebo [3] Disease Context - Myotonic dystrophy type 1 (DM1) is a rare genetic neuromuscular disease affecting approximately 40,000 people in the U.S. and 55,000 in the EU, characterized by high morbidity and early mortality [5] - Symptoms of DM1 can vary widely and include muscle weakness, myotonia, cognitive impairments, and other systemic issues, with no approved disease-modifying treatments currently available [5]

FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing its New Drug Application (“NDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), PIK3CA wild-type advanced ...

Production ramp-up well underwayHighlights Q4 2025: Sold 7,434 ounces gold and 2,634 ounces silver, at average prices of US$4,153 and US$53, respectively, for US$31M in gross project revenuesAveraged 77% of the 1,950 tonne per day design capacity during quarterReached nameplate mill throughput for much of DecemberProcessed 144,845 tonnes of ore, averaging 2.0 g/t goldCompleted 5,433 metres drilling at the Dark Horse and Altan Arrow gold prospects near Bayan Khundii – results expected in Q1 2026 HALIFAX, Nov ...

The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering readinessPHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to an ...

WASHINGTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) has announced the appointment of Ernesto Estrada González as a Senior Managing Director in the Litigation and Dispute Resolution practice within the firm’s Economic Consulting segment in Mexico City, Mexico. Dr. Estrada will lead FTI Consulting’s Litigation and Dispute Resolution practice within Mexico, bringing more than 25 years of experience in economic analysis, competition policy, regulation and complex dispute matters. His ...

The Company is accelerating expansion efforts with plans to commence production in two additional greenhouses and planting its first production intended for sale in markets outside of California. Accelerated expansion comes with confidence in restoration of existing operations and in anticipation of developing new business opportunities including international export and a reimbursable CBD market.The Company is actively working to develop hemp and international markets to expand the total addressable market ...

MARYSVILLE, Ohio, Jan. 20, 2026 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), the leading marketer of branded consumer lawn and garden products in North America, will release its first quarter financial results on Wednesday, January 28, 2026, prior to the opening of the U.S. financial markets. The Company will host a video presentation via webcast at 9:00 a.m. ET to discuss those results. The webcast will be followed by an audio question-and-answer session. To watch the Company presentatio ...